Hot Pursuit     19-Feb-25
Aurobindo Pharma Ltd Falls 6.07%, BSE Healthcare index Drops 2.12%
Aurobindo Pharma Ltd has lost 9.09% over last one month compared to 8.4% fall in BSE Healthcare index and 1.87% drop in the SENSEX

Aurobindo Pharma Ltd lost 6.07% today to trade at Rs 1093.4. The BSE Healthcare index is down 2.12% to quote at 39374.45. The index is down 8.4 % over last one month. Among the other constituents of the index, Lupin Ltd decreased 4.92% and Zydus Lifesciences Ltd lost 4.06% on the day. The BSE Healthcare index went up 10.16 % over last one year compared to the 3.52% surge in benchmark SENSEX.

Aurobindo Pharma Ltd has lost 9.09% over last one month compared to 8.4% fall in BSE Healthcare index and 1.87% drop in the SENSEX. On the BSE, 14807 shares were traded in the counter so far compared with average daily volumes of 14676 shares in the past one month. The stock hit a record high of Rs 1592.55 on 13 Sep 2024. The stock hit a 52-week low of Rs 985 on 13 Mar 2024.

Previous News
  Lupin rallies after receiving USFDA nod for Tolvaptan tablets
 ( Hot Pursuit - 24-Apr-25   11:40 )
  Lupin receives USFDA approval for Tolvaptan Tablets
 ( Corporate News - 24-Apr-25   11:06 )
  Aurobindo Pharma rallies after arm receives USFDA nod for Dasatinib tablets
 ( Hot Pursuit - 23-Apr-25   12:05 )
  Lupin gets EIR from USFDA for Nagpur facility
 ( Hot Pursuit - 17-Apr-25   15:00 )
  Zydus Lifesciences Ltd leads losers in 'A' group
 ( Hot Pursuit - 16-Apr-25   15:00 )
  Aurobindo Pharma rallies after receiving USFDA nod for Rivaroxaban tablets
 ( Hot Pursuit - 15-Apr-25   10:07 )
  Aurobindo Pharma gets USFDA nod for Rivaroxaban tablets
 ( Hot Pursuit - 14-Apr-25   08:59 )
  Zydus receives USFDA approval for Jaythari® (Deflazacort) Tablets
 ( Corporate News - 12-Apr-25   13:35 )
  Zydus Life gets USFDA nod for Deflazacort tablets to treat Duchenne muscular dystrophy
 ( Hot Pursuit - 12-Apr-25   10:22 )
  USFDA inspects Aurobindo Pharma's Raleigh Plant in North Carolina
 ( Corporate News - 11-Apr-25   15:22 )
  CuraTeQ Biologics completes Phase 1 study of denosumab biosimilar, BP16
 ( Corporate News - 09-Apr-25   20:47 )
Other Stories
  Orient Electric Q4 PAT soars 144% YoY to Rs 31 crore
  25-Apr-25   15:20
  Atul gains after Q4 PAT soars 117% YoY; declares dividend of Rs 25/sh
  25-Apr-25   15:20
  Oriental Hotels PAT rises 8% YoY in Q4 FY25
  25-Apr-25   15:05
  Maruti Suzuki records PAT of Rs 3,711.1 crore in Q4; Op. EBIT margin at 8.7%
  25-Apr-25   15:00
  VST Industries Ltd leads losers in 'A' group
  25-Apr-25   15:00
  SRM Contractors Ltd leads losers in 'B' group
  25-Apr-25   14:45
  Chennai Petro rises after Q4 PAT skyrockets to Rs 470 crore; declares dividend of Rs 5/sh
  25-Apr-25   14:44
  Volumes soar at Indian Energy Exchange Ltd counter
  25-Apr-25   14:30
  Escorts Kubota announces price hike for tractors effective from May’25
  25-Apr-25   14:21
  Tech Mahindra gains after Q4 PAT rises 19% QoQ; declares dividend of Rs 30/sh
  25-Apr-25   14:20
Back Top